Acarbose

Mechanism of Action

Acarbose functions as a competitive inhibitor of α-glucosidases, enzymes located in the brush border of the small intestine that break down complex carbohydrates into absorbable simple sugars. While the provided evidence does not contain direct studies specifically examining acarbose's mechanism of action, several studies reference α-glucosidase inhibition as a therapeutic target for diabetes management.

The clinical evidence suggests acarbose works by blocking carbohydrate digestion. One completed Phase 3 trial (NCT01177384) evaluated adding sitagliptin to acarbose monotherapy in type 2 diabetes patients, and another Phase 3 study (NCT01242202) assessed combining an SGLT2 inhibitor with "α-glucosidase inhibitor" - the class to which acarbose belongs. A bioequivalence study (NCT01554631) compared different formulations of Glucobay (acarbose's brand name), confirming its established clinical use.

Multiple studies in the evidence examine α-glucosidase inhibitors as a drug class, including novel compounds designed to target these same enzymes that acarbose inhibits. Research on adamantane-triazole hybrids, imidazo[1,2-a]pyridine derivatives, and natural compounds from Asphodelus microcarpus and Cassia javanica flowers all focused on α-glucosidase inhibition for antidiabetic effects, supporting this mechanism's therapeutic relevance.

Evidence Limitations: The provided research does not include direct molecular or pharmacokinetic studies of acarbose itself. The mechanism described is based on acarbose's known drug class (α-glucosidase inhibitors) and related research on similar compounds, rather than specific studies of acarbose's molecular action.

This information is for educational purposes only and should not replace professional medical advice. Consult your healthcare provider regarding diabetes treatment options.